Mechanisms of resistance to therapies targeting BRCA-mutant cancers

Nature Medicine

Volumn 19, Issue 11, 2013, Pages 1381-1388

  Lord, Christopher J ^a   Ashworth, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; DOUBLE STRANDED DNA; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NIRAPARIB; OLAPARIB; PLATINUM DERIVATIVE; TOPOTECAN; VELIPARIB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RESISTANCE; DNA CROSS LINKING; DNA REPAIR; DOUBLE STRANDED DNA BREAK; GENE MUTATION; HOMOLOGOUS RECOMBINATION; LETHALITY; LOSS OF FUNCTION MUTATION; OVARY CANCER; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MICE; MUTATION; NEOPLASMS; PLATINUM COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; SYNTHETIC BIOLOGY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84887431012     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3369     Document Type: Review

References (56)

1. Greaves, M. & Maley, C.C. Clonal evolution in cancer. Nature 481, 306-313 (2012).
2. Ashworth, A., Lord, C.J. & Reis-Filho, J.S. Genetic interactions in cancer progression and treatment. Cell 145, 30-38 (2011).
3. Stratton, M.R. & Rahman, N. The emerging landscape of breast cancer susceptibility. Nat. Genet. 40, 17-22 (2008).
4. TCGA. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
5. Dobzhansky, T. Genetics of natural populations. Xiii. Recombination and variability in populations of Drosophila pseudoobscura. Genetics 31, 269-290 (1946).
6. Hartwell, L.H., Szankasi, P., Roberts, C.J., Murray, A.W. & Friend, S.H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064-1068 (1997).
7. Kaelin, W.G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689-698 (2005).
8. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
9. Bryant, H.E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
10. Fong, P.C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
11. Fong, P.C. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512-2519 (2010).
12. Audeh, M.W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245-251 (2010).
13. Balmaña, J., Domchek, S.M., Tutt, A. & Garber, J.E. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov. 1, 29-34 (2011).
14. Lord, C.J. & Ashworth, A. The DNA damage response and cancer therapy. Nature 481, 287-294 (2012).
15. Gelmon, K.A. et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12, 852-861 (2011).
16. McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115 (2006).
17. Vilar, E. et al. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 71, 2632-2642 (2011).
18. Mendes-Pereira, A.M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315-322 (2009).
19. Brenner, J.C. et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664-678 (2011).
20. Brenner, J.C. et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 72, 1608-1613 (2012).
21. Byers, L.A. et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2, 798-811 (2012).
22. Edwards, S.L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111-1115 (2008).
23. Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-1120 (2008).
24. Ikeda, H. et al. Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. Cancer Res. 63, 2688-2694 (2003).
25. Swisher, E.M. et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581-2586 (2008).
26. Norquist, B. et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008-3015 (2011).
27. Barber, L.J. et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J. Pathol. 229, 422-429 (2013).
28. Issaeva, N. et al. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 70, 6268-6276 (2010).
29. Cao, L. et al. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol. Cell 35, 534-541 (2009).
30. Bunting, S.F. et al. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol. Cell 46, 125-135 (2012).
31. Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17, 688-695 (2010).
32. Jaspers, J.E. et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 3, 68-81 (2013).
33. Zimmermann, M., Lottersberger, F., Buonomo, S.B., Sfeir, A. & de Lange, T. 53BP1 regulates DSB repair using Rif1 to control 5? end resection. Science 339, 700-704 (2013).
34. Di Virgilio, M. et al. Rif1 prevents resection of DNA breaks and promotes immunoglobulin class switching. Science 339, 711-715 (2013).
35. Chapman, J.R. et al. RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection. Mol. Cell 49, 858-871 (2013).
36. Escribano-Díaz, C. et al. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol. Cell 49, 872-883 (2013).
37. Nakada, S., Yonamine, R.M. & Matsuo, K. RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1. Cancer Res. 72, 4974-4983 (2012).
38. Pennington, K.P. et al. 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes. Gynecol. Oncol. 128, 493-499 (2013).
39. Choi, Y.H. & Yu, A.M. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr. Pharm. Des. published online, doi:10.2174/13816128113199990005 (13 May 2013).
40. Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. USA 105, 17079-17084 (2008).
41. Oplustilova, L. et al. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 11, 3837-3850 (2012).
42. Murai, J. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72, 5588-5599 (2012).
43. Satoh, M.S. & Lindahl, T. Role of poly(ADP-ribose) formation in DNA repair. Nature 356, 356-358 (1992).
44. McCabe, N. et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly(ADP-Ribose) polymerase: an issue of potency. Cancer Biol. Ther. 4, 934-936 (2005).
45. Pettitt, S.J. et al. A genetic screen using the piggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS ONE 8, e61520 (2013).
46. Patel, A.G. et al. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J. Biol. Chem. 287, 4198-4210 (2012).
47. Liu, X. et al. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol. Cancer Res. 7, 1686-1692 (2009).
48. Klauke, M.L. et al. Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer. Virchows Arch. 461, 425-431 (2012).
49. Gottipati, P. et al. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res. 70, 5389-5398 (2010).
50. Drost, R. et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 20, 797-809 (2011).
51. Graeser, M. et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 16, 6159-6168 (2010).
52. Hidalgo, M. et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 10, 1311-1316 (2011).
53. Luo, J., Solimini, N.L. & Elledge, S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
54. Tischler, J., Lehner, B. & Fraser, A.G. Evolutionary plasticity of genetic interaction networks. Nat. Genet. 40, 390-391 (2008).
55. Kumar, M.S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642-655 (2012).
56. Brough, R. et al. Functional viability profiles of breast cancer. Cancer Discov. 1, 260-273 (2011)